Literature DB >> 30838457

Selective Serotonin Reuptake Inhibitors.

Dee Lochmann1, Tara Richardson2.   

Abstract

The first antidepressants were created by chance but brought the idea that central serotonin agonism produced an antidepressant effect. SSRIs were the first class of psychotropic medications to be rationally designed, meaning that researchers intended to utilize a specific mechanism of action while avoiding adverse effects. In this way, SSRIs were created to be safer and more tolerable than previous antidepressants. SSRIs share many similarities, but differ in terms of pharmacokinetics and effects on CYP450 enzymes, which is detailed in this chapter. Further information will be provided regarding safety, clinical indications/uses, and dosing recommendations.

Entities:  

Keywords:  Citalopram; Escitalopram; Fluoxetine; Fluvoxamine; Paroxetine; Rational drug development; Selective serotonin reuptake inhibitors; Sertraline; Side effects; Tolerability; Vilazodone; Vortioxetine

Mesh:

Substances:

Year:  2019        PMID: 30838457     DOI: 10.1007/164_2018_172

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  13 in total

1.  Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.

Authors:  Katelyn M Rossow; Ida T Aka; Angela C Maxwell-Horn; Dan M Roden; Sara L Van Driest
Journal:  Pediatrics       Date:  2020-12       Impact factor: 7.124

2.  Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant.

Authors:  Hung-Tsung Hsiao; Jeffrey Chi-Fei Wang; Sheng-Nan Wu
Journal:  Biomedicines       Date:  2022-06-03

3.  Disturbance of neurotransmitter metabolism in drug-naïve, first-episode major depressive disorder: a comparative study on adult and adolescent cohorts.

Authors:  Liwei Wang; Ping Yang; Chao Yang; Dong Yang; Xiangxin Wu; Ting Cao; Cuirong Zeng; Qian Chen; Shuangyang Zhang; Zhenyu Zhu; Shimeng Jiao; Hualin Cai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-11       Impact factor: 5.760

4.  Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions.

Authors:  Qiuying Li; Hua Huo; Wenli Hu; Yin Sui; Yunbiao Tang
Journal:  Drug Des Devel Ther       Date:  2020-11-24       Impact factor: 4.162

Review 5.  A Review of Ocular Complications Associated with Medications Used for Anxiety, Depression, and Stress.

Authors:  Paul A Constable; Dalia Al-Dasooqi; Rhiannon Bruce; Mallika Prem-Senthil
Journal:  Clin Optom (Auckl)       Date:  2022-02-24

6.  Amelioration of Scopolamine-Induced Amnesic, Anxiolytic and Antidepressant Effects of Ficus Benghalensis in Behavioral Experimental Models.

Authors:  Humna Malik; Sana Javaid; Muhammad Fawad Rasool; Noreen Samad; Syed Rizwan Ahamad; Faleh Alqahtani; Imran Imran
Journal:  Medicina (Kaunas)       Date:  2020-03-23       Impact factor: 2.430

7.  Pro-neurogenic effect of fluoxetine in the olfactory bulb is concomitant to improvements in social memory and depressive-like behavior of socially isolated mice.

Authors:  Leonardo O Guarnieri; Ana Raquel Pereira-Caixeta; Daniel C Medeiros; Nayara S S Aquino; Raphael E Szawka; Eduardo M A M Mendes; Márcio F D Moraes; Grace S Pereira
Journal:  Transl Psychiatry       Date:  2020-01-27       Impact factor: 6.222

Review 8.  Advances in Treatment of Post-Traumatic Stress Disorder with Chinese Medicine.

Authors:  Guang-Tao Hu; Yong Wang
Journal:  Chin J Integr Med       Date:  2021-05-31       Impact factor: 1.978

Review 9.  Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.

Authors:  Sonya C Tang Girdwood; Katelyn M Rossow; Sara L Van Driest; Laura B Ramsey
Journal:  Pediatr Res       Date:  2021-04-06       Impact factor: 3.756

10.  Activation of the p11/SMARCA3/Neurensin-2 pathway in parvalbumin interneurons mediates the response to chronic antidepressants.

Authors:  Gali Umschweif; Lucian Medrihan; Kathryn A McCabe; Yotam Sagi; Paul Greengard
Journal:  Mol Psychiatry       Date:  2021-03-15       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.